Turnaround Atlas Awards

Turnaround Atlas Awards Announced – LM+Co earns three, including Boutique Consulting Firm of the Year

May 21, 2019: Winners throughout the restructuring and M&A communities were honored at the 11th Annual Turnaround Atlas Awards Gala and ceremony celebration, hosted by the Global M&A Network, and held in New York. The independently governed awards recognize excellence in categories of transactions, outstanding firms, top U.S.A professionals and legendary leaders in law, investment banking, restructuring advisory and private equity.

“The Turnaround Atlas Awards validate excellence, tireless work of professionals and firms from the industry. Winners should take pride for effectuating successful restructurings, proving their creativity, expertise and differentiated talents” said Shanta Kumari, CEO and Global Group Editor at Global M&A Network.

Loughlin Management Partners received three awards.  The Firm won Outstanding Healthcare Services Restructuring of 2018 for the restructuring and refinancing of ProCure Proton Therapy Center.  

The LM+Co team implemented operational and financial strategies to grow patient volume, increase reimbursement per treatment, improve collections and mend relationships with the local physician group. These strategies helped the Center increase revenue and profitability. With the successful operational turnaround, LM+Co advised the Center on completing a $150 million tax-exempt bond and subordinated bond transaction. Proceeds of the financing were used to refinance debt and to buyout the Center’s former ownership group by the Public Finance Authority.  With access to longer

LM+Co Capital’s leadership as advisor to the debtor throughout the Xpress Global Systems restructuring and its acquisition by Aterian Investment Partners earned the Firm recognition for 2018 Logistics & Transportation Restructuring of the Year.

XGS is the leading specialized LTL provider of time-definite surface transportation, warehousing, distribution and related value-added services to the Floor Covering Industry. The Company operates 28 service centers across the United States and services more than 3,000 customers. XGS is the leading specialized LTL provider of time-definite surface transportation, warehousing, distribution and related value-added services to the Floor Covering Industry. The Company operates 28 service centers across the United States and services more than 3,000 customers.  The completion of this sale preserved hundreds of jobs, and established a solid platform to explore and launch additional growth initiatives.

XGS Chief Executive Officer Darrel Harris previously noted, “The LM+Co team was instrumental in managing the various complexities of this transaction. They provided strong support and expertise throughout the sale process.”

LM+Co was named USA Boutique Consulting Firm of the Year.

“The entire Loughlin Management team is proud of our colleagues who were honored for their fine work”, commented Jim Loughlin, founding partner and managing director. “We are very pleased that our Firm has been recognized once again for our success creating sustainable value for our clients.

About Loughlin Management Partners + Co
In Private Equity Value Creation, Turnaround + Restructuring and Corporate Finance, LM+Co has distinguished itself by focusing on identifying and implementing actionable solutions and delivering results that maximize enterprise value. LM+Co has a dedicated healthcare team that can assist companies to improve operations through revenue enhancement, cost reduction and working capital improvements.  The firm provides interim management solutions, with an emphasis on revenue cycle, performance improvement, and regulatory/ compliance projects.  For further information, please see www.lmcopartners.com

Ares Commercial Finance Provides $32MM Facility to Confluence Outdoor

LM+Co advised new ownership on this transaction.

ABF JOURNAL

Ares Commercial Finance provided a $32 million senior secured revolving line of credit to Confluence Outdoor.

The proceeds of the transaction will be used to refinance the company’s existing debt and to provide ongoing working capital to support the company’s growth.

Located in Greenville, SC, Confluence Outdoor is a portfolio of seven premier watersport brands including Wilderness Systems, Perception Kayaks, Dagger, Mad River Canoe, Adventure Technology Paddles, Harmony Gear Accessories, and Boardworks Surf.

Ares Commercial Finance is the asset-based lending group of Ares Management. It provides asset-based revolving lines of credit, term loans and stretch loans to middle market and lower-middle market companies.

LM+Co Capital Completes Sale of Xpress Global Systems

Press Release

Chattanooga, Tennessee – December 21, 2018 – LM+Co Capital, a New York-based middle market investment banking firm, is pleased to announce the sale of its client Xpress Global Systems (“XGS” or the “Company”) to Aterian Investment Partners (“Aterian”). Weil Gotshal & Manges LLP advised Aterian, and Reed Smith LLP advised XGS. Financial terms of the transaction were not disclosed.

XGS is the leading specialized LTL provider of time-definite surface transportation, warehousing, distribution and related value-added services to the Floor Covering Industry. The Company operates 28 service centers across the United States and services more than 3,000 customers.

Richard Zytkowicz, Managing Director with LM+Co Capital, stated “LM+Co Capital is very excited for Darrel Harris and his management team as they embark on the next chapter with the Company. Mr. Harris is a very successful CEO and operator with a proven track record in the Transportation Industry. The completion of this sale establishes a solid platform to explore and launch additional growth initiatives. We are honored to have been involved in such an exciting transaction”.

XGS Chief Executive Officer Darrel Harris noted, “Rick and the LM+Co team were instrumental in managing the various complexities of this transaction. They provided strong support and expertise throughout the sale process.”

About LM+Co Capital

LM+Co Capital is an independently operated affiliate of Loughlin Management Partners + Company, a multi-disciplinary professional services firm focused on the middle market. LM+Co Capital, a registered broker dealer and member of FINRA/SIPC, is solely focused on the middle market, providing investment banking and advisory services to corporations, investors, private equity groups and business owners. LM+Co Capital offers its clients years of experience in Mergers + Acquisitions, Capital Advisory, Financial Restructuring and Business Valuations.

About Aterian Investment Partners

Aterian Investment Partners is an operationally-focused middle market private equity firm that provides resources to companies to further enhance growth, operations and investment initiatives. The firm invests in businesses generating $25 million to $500 million of annual revenue with strong, proven franchises.

LM+Co COMPLETES SUCCESSFUL REFINANCING OF THE PROCURE PROTON THERAPY CENTER IN NEW JERSEY

Somerset, New Jersey (September 19, 2018) — Loughlin Management + Company, a New York-based firm, focused on operational and financial turnarounds, announced the successful refinancing of its client, ProCure Proton Therapy Center (“ProCure”), located in Somerset, New Jersey.  

The LM+Co team implemented operational and financial strategies to grow patient volume, increase reimbursement per treatment, improve collections and mend relationships with the local physician group. These strategies have helped the Center increase revenue and profitability.  With the successful operational turnaound, LM+Co advised the Center on completing a $150 million tax-exempt bond and subordinated bond transaction. Proceeds of the financing were used to refinance debt and to buyout the Centers’ former ownership group by the Pubic Finance Authority.  With access to longer term financing, the Center is well positioned for future growth. 

About ProCure Proton Therapy Center in Somerset, New Jersey
ProCure Proton Therapy Center, was the first proton treatment center in the NY/NJ/CT tri-state area and the 10th facility in the United States. ProCure has treated over 3,000 patients since opening its doors in 2012, providing access to cancer patients from New Jersey and across the world, with this life-changing treatment.  Today, ProCure remains the only multi-room proton center in the tri-state area and is the only center with the precise pencil beam scanning capabilities. 

Proton therapy is an advanced form of radiation that destroys cancer cells by preventing them from dividing and growing. Unlike standard X-ray radiation, it uses protons – positively charged sub-atomic particles – which precisely target tumors. Proton therapy reduces the risk of damage to healthy tissue and organs near the tumor, and potentially allows patients to receive higher, more effective doses of radiation, but with fewer side effects.

About Loughlin Management Partners + Co
In Private Equity Value Creation, Turnaround + Restructuring and Corporate Finance, LM+Co has distinguished itself by focusing on identifying and implementing actionable solutions and delivering results that maximize enterprise value. LM+Co has a dedicated healthcare team that can assist companies to improve operations through revenue enhancement, cost reduction and working capital improvements.  The firm provides interim management solutions, with an emphasis on revenue cycle, performance improvement, and regulatory/ compliance projects.  For further information, please see www.lmcopartners.com

California Proton Therapy Center, LLC Re-Launches California Protons

SAN DIEGO, Dec. 7, 2017 /PRNewswire/ — California Proton Therapy Center, LLC today announced the official re-launch of California Protons, a cancer treatment center located at 9730 Summers Ridge Road in San Diego. California Protons features an expanded physician group and new management team and ownership, effectively positioning the Center for continued excellent patient care, as well as growth and success.

All of the treatment rooms at California Protons are equipped with the most advanced proton beam technology, allowing doctors to treat even the most complex and aggressive cancers. The Center uses pencil-beam scanning technology to precisely target tumors while protecting healthy, normal tissue and surrounding organs. Protons can be delivered within an accuracy of less than two millimeters, making this treatment especially effective at combatting cancer in sensitive areas such as the brain, spine, lung, breast and prostate, and is widely regarded as the best option for treating pediatric patients with cancer.

Dr. Andrew L. Chang, the department Chief of Pediatric Cancers at California Protons, is president of the Proton Doctors Professional Corporation (PDPC), the oncologist group providing clinical leadership at the Center. Dr. Carl Rossi, who has treated more than 9,000 prostate cancer patients with proton therapy—more than any other physician in the world—is the Medical Director of the Center. The Center’s physicians have more than 50 years of collective proton therapy experience.

“At California Protons, we are committed to continuing the delivery of outstanding and effective patient care,” says Dr. Carl Rossi. “By expanding our existing affiliations with the University of California, Rady Children’s Hospital in San Diego and other healthcare institutions throughout the state, we will increase patient access to the Center and, among other things, enhance our ability to participate in clinical trials and research.”

“The Center has been recapitalized and the investor group has provided additional financial support to allow the Center to grow,” says James J. Loughlin, Jr., Managing Partner at Loughlin Management Partners + Co., the healthcare turnaround specialists who are working with the physicians and ownership on the transition plan. “The re-launch of the Center as California Protons is an exciting event and we look forward to a highly successful future working with the team of expert proton physicians, nurses, physicists, technologists and dosimetrists at the Center to make this state-of-the-art cancer fighting tool available to all of the residents of San Diego and California.”

About California Protons
One of only two proton therapy centers in California and 25 nationwide, California Protons combines cutting-edge proton treatment capabilities with a team of radiation oncologists who amass more than 50 years of collective proton therapy experience. The Center leverages revolutionary intensity-modulated pencil-beam scanning technology to release a high dose of cancer-killing radiation that conforms precisely to the unique shape and size of the tumor. This approach effectively targets and treats even the most complex and aggressive cancers, sparing surrounding healthy tissues and organs. For more information, please visit www.CaliforniaProtons.com.

About Loughlin Management Partners + Co
In Private Equity Value Creation, Turnaround + Restructuring and Corporate Finance, LM+Co has distinguished itself with management teams and investors for more than a decade by focusing on actionable solutions across a broad range of industries, and delivering results that maximize value. LM+Co provides a full range of advisory services to companies and their investors, as volatility continues in global energy markets. LM+Co’s Energy + Power team can help companies adjust their strategies, restructure their operations and capital structures to confront turbulent market conditions. For further information, please see www.lmcopartners.com

LM+Co Capital Completes Successful Refinancing of TruFood Mfg., Inc.

Pittsburgh, Pennsylvania – April 28, 2017

LM+Co Capital, a New York-based middle market investment banking firm, announced today the successful refinancing of its client TruFood Mfg., Inc. (“TruFood”), based in Pittsburgh, Pennsylvania. BHI (Bank Hapoalim B.M.) and AloStar Capital Finance acted as co-agents on the refinancing transaction. Financial terms of the transaction were not disclosed.

TruFood is a leading East Coast snack food contract manufacturer of well-recognized brands serving the health-conscious, “on-the-go” consumer market. This family-owned business operates in the highly competitive Contract Food Manufacturing Industry where high-touch customer service, quality product execution and new product development is critical to success. TruFood manufactures a full range of snack products including granola products, baked bars, nutrition bars, layered protein bars and molded chocolate products.

Richard Zytkowicz, Managing Director with LM+Co Capital, stated “LM+Co Capital is delighted for Pete Tsudis and his management team as they embark on the next chapter of the TruFood legacy. Mr. Tsudis is a very successful CEO and operator with a proven track record in the Contract Food Manufacturing Industry. The completion of this refinancing transaction affords TruFood the opportunity to further expand its product offerings and establish a solid platform to explore and launch additional growth initiatives. We are honored to have been involved in such an exciting transaction”.

TruFood President and Chief Executive Officer Pete Tsudis noted, “Our partnership with Rick and the LM+Co team has been tremendously successful. They provided invaluable support and expertise throughout our refinancing process”.

About TruFood Mfg., Inc.
TruFood was founded in 1985 by Spiro Tsudis, father of current CEO, Peter Tsudis, to produce children’s fundraising chocolate candy. When Pete assumed control of TruFood in 2001, he quickly realized the various trends in the snack food market were changing to healthier forms of snack consumables and began to position TruFood to capture these manufacturing opportunities.

Today, TruFood partners with various multi-national companies to manufacture a variety of well-recognized snack brands. TruFood has a large presence on the East Coast with over 350,000 sq.ft. of state-of-the-art manufacturing facilities and continues to grow through its strong reputation for manufacturing high quality snack products for its marquee customer base.

About LM+Co Capital
LM+Co Capital is an independently operated affiliate of Loughlin Management Partners + Company, a multi-disciplinary professional services firm focused on the middle market. LM+Co Capital, a registered broker dealer and member of FINRA/SIPC, is solely focused on the middle market, providing investment banking and advisory services to corporations, investors, private equity groups and business owners. LM+Co Capital offers its clients years of experience in Mergers + Acquisitions, Capital Advisory, Financial Restructuring and Business Valuations.

About Bank Hapoalim B.M. (“BHI”)
BHI offers full commercial banking services that combine the personal attention and responsiveness of a prestigious boutique bank with the expertise and financial strength of a global bank. With a footprint in the largest U.S.  metropolitan areas, BHI is committed to creating innovative funding solutions for long and short term needs, and providing convenient banking and liquidity products for everyday business needs.

As part of the Bank Hapoalim Group, BHI is backed by the financial strength of a leading financial institution, giving BHI’s U.S. customers access to business financing from one of the world’s most stable banking environments.

About AloStar Capital Finance
AloStar Capital Finance offers needed capital and counsel to business leaders across America who are creating their own success stories. Through our Business Credit, Lender Finance and Real Estate Finance platforms, we create customized lending solutions for customers with capital requirements up to $60 million. To date, AloStar has closed more than 160 deals with commitments totaling more than $2 billion. At AloStar, you’ll have ready access to decision makers with deep capital industry experience who are responsive, flexible and eager to help you write your success story.

AloStar Capital Finance is a trade name of AloStar Bank of Commerce, Member FDIC. For more information, visit www.AloStarBank.com.

*LM+Co Capital is an independently operated affiliate of LM+Co. A licensed broker dealer, LM+Co Capital is registered with FINRA, SIPCFor a summary of LM+Co Capital’s registration with FINRA, go to BrokerCheck.

 

 

Owners of Scripps Proton Therapy Center File for Bankruptcy

As Reported in San Diego Business Journal |March 2, 2017

The owner of Mira Mesa’s 3-year-old Scripps Proton Therapy Center has filed for Chapter 11 bankruptcy protection after failing to attract and receive reimbursement for treating a sufficient number of patients.

California Proton Treatment Center LLC said it has arranged a $16 million bridge loan it will use to continue operations at the $225 million facility managed by Scripps Health.

“Our doors will remain open to administer highly specialized cancer therapies, and a patient ombudsman will ensure that our transition to a new organizational framework won’t affect patients or staff,” CPTC’s chief restructuring officer, Jette Campbell, said in a news release.

Proton therapy is a form of precisely targeted radiation proponents say focuses on tumors while sparing surrounding tissue that might be damaged by conventional X-ray therapy. There are three such facilities in California and at least two dozen nationwide.

The bankruptcy filing came six months after Scripps increased the number of patients it treats at the center without receiving prior authorization by health plans. Scripps officials said in November the move led to a 15 percent to 20 percent increase in patient volume at the five-room, 102,000-square-foot facility.

Scripps said at the time it was directing more resources to pressuring private insurers to approve proton therapy treatments that can cost $60,000 or more.

CPTC said in a November statement patient access to the therapy had “steadily increased, and our outlook is positive.”

Scripps President and CEO Chris Van Gorder said he did not know about plans for the bankruptcy filing until after it happened, but that the health care system had been anticipating such a move for months because of CPTC’s “enormous amount of debt.”

“Scripps knew that this was a high-risk venture from the very beginning,” he said.

Van Gorder added that shortly before the center’s opening in 2014, commercial insurers shifted away from proton therapy toward a form of conventional treatment that uses a narrow beam of radiation. He said Scripps continues to believe proton therapy is the more effective therapy, largely because protons stop at the target site rather than continuing through a patient’s body.

He said Scripps has no financial exposure to CPTC’s bankruptcy, and that the health system only leases and operates it.

Lately, patient volume at the center has averaged 70 at any given time, even as more than 200 calls per month come in from people interested in receiving treatment there, Van Gorder said, adding that the facility needs a steady flow of 130 to 140 patients to thrive.

Scripps said in a written statement CPTC has asked the San Diego-based health-care system to continue treating patients at the center according to their contractual agreement.

The center’s medical director, Dr. Carl Rossi, said in CPTC’s March 1 news release the bankruptcy filing will “enhance our operations and allow us to administer our advanced proton therapy care to a wider spectrum of patients.” It was unclear from the release how the financial restructuring would accomplish those goals, and Van Gorder said he assumed Rossi was simply referring to expectations the center would continue to operate.

CPTC’s financial struggles surfaced Jan. 25 in a news release by Varian Medical Systems, a Palo Alto-based cancer technology manufacturer. The company said it had taken a $76 million charge relating almost exclusively to CPTC’s indebtedness to Varian and “lower than expected patient volumes that are insufficient to support CPTC’s capital structure.”

Varian’s CEO, Dow Wilson, said his company believes the proton therapy center can get on a more solid financial footing by “serving a broader patient population with additional health care providers locally and regionally.”

In September 2011, Varian and Dallas-based ORIX Capital Markets LLC agreed to loan up to $165.3 million to CPTC to fund the development, construction and initial operations of the Scripps Proton Center.

In November 2015, the two companies entered into a forbearance agreement, together with J.P. Morgan Chase Bank, which had assumed $45 million of the original loan, to delay receiving principal and interest payments until April 2017, subject to certain conditions.

Then, in January, Varian said it was informed CPTC and its loan agent had taken steps to address liquidity problems at CPTC. Varian’s analysis then was that these actions would “likely result in a serious liquidity event at CPTC, possibly leading to insolvency or bankruptcy proceedings at CPTC.”

In response, Varian decided to impair $38 million of the $98 million, including $29 million in accrued interest, still owed to the company by CPTC.

Loughlin Management Partners has been retained as financial advisor to the Senior Lender’s on this matter.

Erickson Inc. plan of reorganization confirmed by bankruptcy court

As first reported at Erickson Incorporated |March 21, 2017

Erickson’s restructuring will reduce the company’s pre-bankruptcy debt by more than $400 million upon emergence. In order to improve its capital structure and finance its exit from bankruptcy, Erickson was able to (i) obtain a commitment for an asset-based lending facility with a borrowing capacity of up to $150 million, led by MidCap Financial Trust, (ii) reach an agreement on non-cash repayment for $69.8 million in financing obtained during the bankruptcy, and (iii) secure a backstopped $20 million rights offering.

“These financial commitments demonstrate the creditor interest and support in restructuring Erickson’s financial affairs, servicing customer contracts, and enabling Erickson to continue operating well into the future. I am pleased and appreciative of our employees, customers and stakeholders who have supported us throughout this challenging process,” said Erickson president and CEO Jeff Roberts.

With the overwhelming support of all classes of creditors entitled to vote on the plan, Erickson will emerge from bankruptcy with the ability to grow its existing business segments of civil aviation, global defense and security, and manufacturing and maintenance, repair and overhaul (MRO).

“Erickson is extremely satisfied with this quick and successful outcome,” said Erickson CFO David Lancelot. “Erickson’s successful restructuring would not have been possible without the strong support of our funded debtholders and aircraft lessors. The financial impact of this approved plan is very positive and allows us to be far more strategic to compete in the competitive landscape. Haynes and Boone, LLP is Erickson’s restructuring counsel and other restructuring professionals included Imperial Capital, LLC and Alvarez and Marsal North America, LLC.

RadioShack Files for Bankruptcy (Again), Closing 200 Stores

As first reported in InvestorPlace |Mar 9, 2017 |12:43 pm EDT

General Wireless, which operates as RadioShack, is filing for bankruptcy again just two years after it came out of its last bankruptcy.

RadioShack says that it will be closing 200 of its stores at it enters Chapter 11 bankruptcy protection. This will leave it with 1,300 stores still open and it plans to evaluate what to do with these locations.

RadioShack notes that it many choose to keep its remaining 1,300 stores open on an ongoing basis. It claims that this may be the best way to maximize value for creditors. However, it also says it will explore other strategic options.

RadioShack says that it was making efforts toward returning to profitability after coming out of its bankruptcy two years ago. This includes reducing operating expenses by 23% in 2016 and gross profit dollars going up by 8% during that year. However, it still had problems.

“For a number of reasons, most notably the surprisingly poor performance of mobility sales, especially over recent months, we have concluded that the Chapter 11 process represents the best path forward for the Company,” Dene Rogers, President and CEO of RadioShack , said in a statement. “We will continue to work with our advisors and stakeholders to preserve as many jobs as possible while maximizing value for our creditors.”

RadioShack points out in its bankruptcy announcement that Sprint Corp (NYSE:S) was its partner responsible for managing its mobility business. General Wireless is a joint venture between Sprint and Standard General.

RadioShack says that it will post additional information concerning the bankruptcy on its website. Legal documents will be available on the Prime Clerk website. Prime Clerk is the company’s claims agent. It is also getting legal advice from Pepper Hamilton LLP and Jones Day.

Loughlin Management Partners has been retained to serve as financial advisor to General Wireless.

PROCURE PROTON THERAPY NEW JERSEY CELEBRATES FIVE YEARS OF SERVICE TO CANCER COMMUNITY

As first reported at www.procure.com |March 21, 2017

SOMERSET, N.J. (March 21, 2017) – Yesterday, ProCure Proton Therapy Center in Somerset, N.J., celebrated its five-year anniversary. As the first proton treatment center in the tri-state area and the 10th facility in the nation, ProCure is proud to have connected cancer patients and their families, from New Jersey and across the globe, with this life-changing treatment.

Proton therapy is an advanced form of radiation that destroys cancer cells by preventing them from dividing and growing. Unlike standard X-ray radiation, it uses protons – positively charged sub-atomic particles – which precisely target tumors. Proton therapy reduces the risk of damage to healthy tissue and organs near the tumor, and potentially allows patients to receive higher, more effective doses of radiation, but with fewer side effects.

Much to celebrate, and to honor
The anniversary converges with another important ProCure milestone: two weeks ago, the Center graduated its 2,500th patient. To celebrate, new and past graduates, alongside friends, family and ProCure staff, gathered together at the Center for a special graduation ceremony that honored the patient journey and the fight against cancer. The afternoon was rife with inspiring speeches, positive energy and a steadfast sense of community; it was a quintessential ProCure event.

Former ProCure patient Bob Jones is no stranger to these special ProCure moments. Five years ago, he entered the Center seeking treatment for prostate cancer, and was ultimately deemed cancer-free after 44 sessions and countless friendships formed. Bob was the 10th patient to graduate from ProCure, and has been an active member of the Patient Ambassador program since – attending graduations most weeks, sharing his story with others and lending advice to men facing prostate cancer.

“My experiences here in the span of five years – both as a patient and a friend of the Center – have been exceptional. The team here is kind, generous and compassionate, and I’m fortunate to be able to pay it forward through my role as an Ambassador,” Bob reflects. “It’s hard to explain the magic of this place to those unfamiliar – but it’s real, and it’s genuine, and patients are lucky enough to experience it while fighting cancer.”

Victor Lawson, another patient from the first class of 2012 graduates, also treated for prostate cancer, echoes many of Bob’s sentiments: “For me, ProCure played a critical role in my cancer treatment journey. In addition to offering me such great care five years ago, every time I return I’m greeted with the same welcoming atmosphere as when I first walked through the front doors on day one. The connections I’ve made here, both with staff and other patients, will remain my most fond memories of ProCure.”

ProCure’s first-ever patient graduate, Frank Mackinson, who was treated for a plasmacytoma of the skull base, adds, “They raise the bar tremendously as far as care and personalization goes. Since I’ve completed treatment at ProCure, it has been a joy to return to this pleasant facility and supportive community.”

Best-in-class treatment and services
ProCure New Jersey is the only proton therapy center in the metro NY/NJ area equipped with pencil beam scanning (PBS) – the most advanced proton therapy technology available today. The technique moves a proton beam of pencil-point sharpness back and forth across each layer of a tumor’s thickness and paints the tumor with radiation in three dimensions, rendering it ultra-precise and ideal for tumors located next to critical organs, such as those in the prostate, lungs, brain, head and neck, among others. PBS is also effective for pediatric cancers, where sparing healthy tissue is especially important for healthy development. ProCure’s PBS technology expands the center’s ability to treat difficult and complicated tumors, and is reflective of its commitment to continually advance cancer treatment options.

Over the past five years, ProCure has also worked closely with patients and their families to create tailor-made treatment plans that address each patient’s unique needs. The range of support available to patients extends from traditional care and pushing technological boundaries to insurance and financial counselors, a special pediatric playroom for patients and children of patients, and a concierge program to address personal needs like local accommodations.

“In the five years that ProCure’s been around, what’s struck me the most – in addition to our scientific capabilities – was how we’ve elevated patient needs and comfort as paramount values,” states Brian Chon, MD, treating oncologist and Medical Director of the Center. “The team goes above and beyond to make each person who walks through our doors feel like an individual — not just a cancer patient, not just an anonymous case file. It’s simply in the fabric of our culture.”

Dr. Chon continues, “We’re proud to have brought the unique properties of proton therapy to a diverse group of tumor types and cancer patients over these last five years. We will use this milestone to reflect on where we’ve been, how far we’ve come, and how we will work tirelessly to help our patients and the cancer community in the future.”